Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ipsen
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Provision of written informed consent prior to any study related procedures.
postmenopausal or ovariectomised female patient over 18 years of age.
histologically confirmed diagnosis of ER positive endometrial carcinoma in the primary tumour or metastatic disease
patient has received one line of chemotherapy prior to enrolment in the adjuvant or in the metastatic setting (including chemoradiotherapy) and progressed after this line of chemotherapy
patient has at least one measurable disease site (RECIST criteria version 1.1)
You may not be if
patient has received hormone therapy for endometrial cancer in the adjuvant or metastatic setting
patient has received more than one line of chemotherapy in the adjuvant or metastatic setting
patient was treated with any other investigational agent within the 3 weeks before study entry.
patient has ongoing cardiac dysrhythmias grade ≥2, atrial fibrillation of any grade (NCI CTCAE) or QTcF interval \>460 msec.
Clareo Health | Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
